Harnessing the prognostic power of preoperative systemic immune-inflammation index/albumin ratio in hepatocellular carcinoma resection.

IF 1.8 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY
Zhao-Nan Zhang, Liang Hao, Shuang Han, Shan-Shan Li, Si-Xiang Lin, Yan-Dong Miao
{"title":"Harnessing the prognostic power of preoperative systemic immune-inflammation index/albumin ratio in hepatocellular carcinoma resection.","authors":"Zhao-Nan Zhang, Liang Hao, Shuang Han, Shan-Shan Li, Si-Xiang Lin, Yan-Dong Miao","doi":"10.4240/wjgs.v17.i2.102261","DOIUrl":null,"url":null,"abstract":"<p><p>The recent study by Chen <i>et al</i>, published in the <i>World Journal of Gastroenterology</i>, introduces a groundbreaking assessment tool-the preoperative systemic immune-inflammation index/albumin (SII/ALB) ratio-for patients with hepatocellular carcinoma (HCC) undergoing curative resection. This study not only establishes the independent prognostic significance of the SII/ALB ratio but also incorporates it into a predictive nomogram, enhancing its utility for clinical decision-making. The SII/ALB ratio, by integrating inflammatory and nutritional biomarkers, offers a novel lens through which the prognosis of HCC patients can be viewed, suggesting a more tailored approach to patient management. The development of the nomogram, validated for its accuracy in predicting patient outcomes, marks a pivotal advance, potentially guiding surgical decisions and postoperative care. However, the study's focus on a single-center cohort prompts the need for validation in a broader, more diverse patient population to ensure its applicability across various clinical settings. Moreover, longitudinal studies could elucidate the dynamic changes in SII/ALB post-surgery, offering insights into its potential as a continuous monitor for recurrence and long-term survival. This abstract aim to underscore the critical findings of Chen <i>et al</i>'s study while calling for further research to explore the full potential of the SII/ALB ratio in the global management of hepatocellular carcinoma.</p>","PeriodicalId":23759,"journal":{"name":"World Journal of Gastrointestinal Surgery","volume":"17 2","pages":"102261"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886000/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4240/wjgs.v17.i2.102261","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The recent study by Chen et al, published in the World Journal of Gastroenterology, introduces a groundbreaking assessment tool-the preoperative systemic immune-inflammation index/albumin (SII/ALB) ratio-for patients with hepatocellular carcinoma (HCC) undergoing curative resection. This study not only establishes the independent prognostic significance of the SII/ALB ratio but also incorporates it into a predictive nomogram, enhancing its utility for clinical decision-making. The SII/ALB ratio, by integrating inflammatory and nutritional biomarkers, offers a novel lens through which the prognosis of HCC patients can be viewed, suggesting a more tailored approach to patient management. The development of the nomogram, validated for its accuracy in predicting patient outcomes, marks a pivotal advance, potentially guiding surgical decisions and postoperative care. However, the study's focus on a single-center cohort prompts the need for validation in a broader, more diverse patient population to ensure its applicability across various clinical settings. Moreover, longitudinal studies could elucidate the dynamic changes in SII/ALB post-surgery, offering insights into its potential as a continuous monitor for recurrence and long-term survival. This abstract aim to underscore the critical findings of Chen et al's study while calling for further research to explore the full potential of the SII/ALB ratio in the global management of hepatocellular carcinoma.

利用术前全身免疫炎症指数/白蛋白比值对肝癌切除术预后的影响。
Chen等人最近发表在《世界胃肠病学杂志》上的研究介绍了一种开创性的评估工具——术前全身免疫炎症指数/白蛋白(SII/ALB)比——用于肝细胞癌(HCC)行根治性切除术的患者。本研究不仅确立了SII/ALB比值的独立预后意义,而且将其纳入预测nomogram,提高了其对临床决策的实用性。SII/ALB比值,通过整合炎症和营养生物标志物,提供了一种新的视角,通过这种视角可以观察HCC患者的预后,为患者管理提供更有针对性的方法。发展的诺模图,验证了它的准确性预测病人的结果,标志着一个重要进步,潜在指导手术和术后护理决策。然而,该研究的重点是单中心队列,因此需要在更广泛、更多样化的患者群体中进行验证,以确保其在各种临床环境中的适用性。此外,纵向研究可以阐明术后SII/ALB的动态变化,为其作为复发和长期生存持续监测的潜力提供见解。本摘要旨在强调Chen等人研究的重要发现,同时呼吁进一步研究以探索SII/ALB比率在肝细胞癌全球管理中的全部潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
5.00%
发文量
111
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信